Summary
A variety of innumerable clinical trials are now carried out all over the world. However, there are few high evidence level results which are usable in actual practice. Moreover, there are very few cases participating in clinical trials, especially in Japan, and the evidence level is becoming low.
However, the data from clinical trials from Japan are necessary to the patients in our country, and from now on, through clinical trials of high quality in the Kyushu and Okinawa districts, we can offer more excellent medical treatment which gives priority to patients. We must make efforts to improve the survival rate of breast cancer in Japan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sugimachi K, Maehara Y, Akazawa K,et al: Postoperative Chemo-endocrine Treatment with Mitomycin C, Tamoxifen, and UFT is Effective for Patients with Premenopausal Estrogen Receptor-positive Stage II Breast Cancer.Breast Cancer Research and Treatment 56:113–124, 1999.
Mitsuyama S, Tashiro H, Koga T,et al: Comparison of CAF Plus MPA with CAF Plus TAM for Advanced or Recurrent Breast Cancer.Jpn J Cancer Chemotherapy 22:2073–2080, 1995.
Mitsuyama S, Ohno S, Koga T,et al: Study on CAF + Medroxyprogesterone acetate (MPA) Treatment for Advanced or Recurrent Breast Cancer-Comparison between MPA 600 mg and 1200 mg-.Jpn J Cancer Chemotherapy 26:2029–2036, 1999.
Mitsuyama S, Kuroda Y, Osato K,et al: Administration Method and Recurrence-preventing Effect of Medroxyprogesterone acetate (MPA) as a Postoperative Adjuvant Endocrine Therapy for Stage II Breast cancer.Jpn J Cancer Chemotherapy 23:1163–1160, 1996.
Mitsuyama S, Anan K, Shimabukuro T,et al: Effectiveness of Postoperative Adjuvant Chemo-endocrine Therapy in Node-positive Breast Cancer.Jpn J Breast Cancer 17:547–553, 2002.
Nishimura R, Nomura Y, Ueno H,et al: Evaluation of Treatment with High-Dose Toremifene in Advanced or Recurrent Breast Cancer That was Resistant to Previous Treatment or had Relapsed.Jpn J Cancer Chemotherapy 15:391–397, 2000.
Ohsaki A, Mitsuyama S, Toge T,et al: Phase I Study of UFT Plus Paclitaxel for Advanced or Recurrent Breast Cancer. Abstract No: OS45-4, The 41th Annual Meeting of Japan Society of Clinical Oncology, 2003.
Ogawa S, Tamura K, Mitsuyama S,et al: Phase I Study of Weekly Paclitaxel as 2nd Line Therapy Included Docetaxel-resistant Advanced or Recurrent Breast Cancer. Abstract NO: A055, The 10th Annual Meeting of the Japanese Breast Cancer Society (JBCS), 2002.
Shimada K, Tamura K, Mitsuyama S,et al: Paclitaxel as 1st Line Therapy for Advanced or Recurrent Breast Cancer. Abstract No: P-248, The 12th Annual Meeting of JBCS, 2004.
Wakamatsu S, Tamura K, Mitsuyama S,et al: Registration of All Breast Cancer Cases in Kyushu and Chugoku Districts. Abstract No: O-019: The 12th Annual Meeting of JBCS, 2004.
Tamaki N, Tamura K, Mitsuyama S,et al: Adriamycin Plus Cyclophosphamide Followed by Paclitaxel as Postoperative Adjuvant Chemotherapy. Abstract No: W2-04: The 12th Annual Meeting of JBCS, 2004.
Hamada Y, Tamura K, Mitsuyama S,et al: Phase I Study of Docetaxel Plus Epirubicin for Advanced or Recurrent Breast Cancer. Abstract No: A-056: The 10th Annual Meeting of JBCS, 2002.
Anan K, Tamura K, Mitsuyama S,et al: Docetaxel Plus Epirubicin as Front-line Therapy for Breast Cancer. Abstract No: B-296: The 11th Annual Meeting of JBCS, 2003.
Tamura K, Mitsuyama, Nishimura R,et al: Phase I Study of Capecitabine Plus Cyclophosphamide for Advanced or Recurrent Breast Cancer. Abstract No: O-025: The 12th Annual Meeting of JBCS, 2004.
Author information
Authors and Affiliations
About this article
Cite this article
Mitsuyama, S. President’s address: History of clinical trials for breast cancer in Kyushu and Okinawa. Breast Cancer 12, 4–10 (2005). https://doi.org/10.2325/jbcs.12.4
Issue Date:
DOI: https://doi.org/10.2325/jbcs.12.4